Japan Daily Briefing

Tokyo Electron (TOELY), Japan's largest semiconductor equipment maker and a global benchmark for the ASML-equivalent CAPEX cycle, crashed 10.74% in one of the largest single-day drawdowns for the stock in recent memory. A drop of this magnitude in a leading semicap name typically precedes a broader reassessment of the global chip equipment investment cycle — either from export control tightening, order cancellation risk, or earnings guidance downward revision. Investors in the global semiconductor supply chain, from TSMC customers to Advantest peers, should watch TOELY's next earnings call closely as a leading indicator for the entire capex cycle.

SoftBank (SFTBY) fell 8.34%, reflecting the broader de-rating of tech-focused investment vehicles as global risk appetite contracts under ECB hawkishness and the Iran war's impact on energy and sentiment. SoftBank's Vision Fund exposure to global AI and late-stage tech companies creates outsized sensitivity to changes in long-duration discount rates — the same dynamic that hammered growth tech in 2022. The question for investors is whether this is a tactical pullback in a recovery trade or a resumption of the structural de-rating that began when Vision Fund II's mark-to-market losses first surfaced.

Takeda Pharmaceutical (TAK) was the standout gainer at +1.04% in a session where virtually every other significant Japan name was in the red — a classic flight to defensive dividend-payers that pharmaceutical stocks represent in a risk-off rotation. Takeda's global drug portfolio insulates it from the export-control risks that are hammering Japan's semiconductor supply chain names, and its USD-denominated royalty income streams benefit from JPY weakness. The divergence between pharma and electronics in this session is a textbook Japan defensive rotation playbook.